BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed AAPG catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:3a3532053e64237b2503@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:AAPG P2 readout (est.): Study of APG-2575 in Patients With Relapsed
 /Refractory CLL/SLL
DESCRIPTION:Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL\
 nNCT05147467 | PHASE2 | RECRUITING | sponsor: Ascentage Pharma Group Inc.\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nDate precision: month (shown on the first day)\nTicker AAPG (confiden
 ce 0.9)\nSource: https://clinicaltrials.gov/study/NCT05147467\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05147467
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1fc6fc360453f2c5f92c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AAPG P3 readout (est.): Global Trial in APG2575 for Patients With C
 LL/SLL
DESCRIPTION:Global Trial in APG2575 for Patients With CLL/SLL\nNCT06104566 
 | PHASE3 | RECRUITING | sponsor: Ascentage Pharma Group Inc.\nPrimary comp
 letion date (ESTIMATED)\; top-line results usually follow later.\nTicker A
 APG (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06104566
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06104566
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
